STAT+: Pharmalittle: We’re reading about Kalshi bets on clinical trials, a Merck cholesterol pill, and more

Kalshi, a major player in prediction markets, is venturing into a new arena by allowing people to place bets on clinical trials and regulatory approvals. This move could offer investors and stakeholders a unique way to gauge the success of drug trials and regulatory processes. It's significant because it introduces a novel method for predicting outcomes in the pharmaceutical industry, which typically relies on complex data and expert analysis. The implications could range from more informed investment decisions to potentially uncovering early signs of trial success or failure.